



YALE PROGRAM IN  
ADDICTION  
MEDICINE

# Year-in- Review

2024-25

The Yale Program in Addiction Medicine (YPAM) works to expand access to high quality prevention, assessment, treatment, and harm reduction services for substance use, substance use disorders, and concomitant conditions.

Our faculty and affiliates provide evidence-based clinical care, conduct rigorous and innovative research, train the next generation of addiction specialists, and engage in policy and advocacy initiatives. We model, and work to advance, patient-centered non-stigmatizing care as the norm, and partner with government, community-based organizations, people who use substances, and their loved ones, to improve the health and wellbeing of all those impacted by addiction.

YPAM is affiliated with several departments, clinics, and initiatives spanning Yale School of Medicine (YSM), Public Health (YSPH), Nursing (YSN), and Law (YLS), Yale New Haven Hospital (YNHH), and Yale New Haven Health.

The Year-in-Review 2024-25 is published by the Yale Program in Addiction Medicine.

Special thanks to:

Julie Parry, MS  
Serena Crawford, MFA  
Amy Anderson  
DIM Communications  
DIM Development

Correspondence about this report may be sent electronically to:

Emma Biegacki, MPH  
Program Manager  
Yale Program in Addiction Medicine  
emma.biegacki@yale.edu

 [addictionmedicine.yale.edu](https://addictionmedicine.yale.edu)

 [@YaleADM](https://twitter.com/YaleADM)

 [@yaleadm.bsky.social](https://bsky.app/profile/yaleadm.bsky.social)

 [@yaleaddictionmed](https://www.instagram.com/yaleaddictionmed)

 [Yale Program in Addiction Medicine](https://www.linkedin.com/company/yale-program-in-addiction-medicine)

# Contents

<b>Message from our Director</b>	3
<b>Program Updates</b>	4
<b>Clinical Practice</b>	5
Treating Alcohol Use in the Setting of Liver Disease Through Integrated Care	6
First Legal Mobile Retail Pharmacy and Clinic Provides Care to People Where They Are	7
Clinical Tools & Resources	8
<b>Education</b>	9
2024-25 Fellowship Graduates	10
Celebrating 6 Years of CHAMP	11
Forging New Paths with SUSTAIN	12
Across the Country: National Engagement Through Addiction Medicine Grand Rounds	13
Around the World: New Haven to Jordan	14
<b>Research</b>	15
At a Glance	16
Medications ‘Gold Standard’ in Preventing Overdoses	17
Interdisciplinary Collaboration and Learning in Alcohol Research	18
Seven-day Buprenorphine is Safe for Those with Minimal Opioid Withdrawal	19
2024-25 Conference Highlights	20
<b>Policy</b>	21
Why Do So Few U.S. Psych Hospitals Use Medications for Opioid Use Disorder?	22
Advising Connecticut on State Opioid Settlement Spending	23
2024-25 Policy Publication Highlights	24
<b>Awards &amp; Recognition</b>	25
<b>Appointments &amp; Promotions</b>	27
<b>In the Media</b>	28
<b>Faculty &amp; Staff</b>	31
<b>Support Our Work</b>	35



# Message from our Director

Welcome to the Yale Program in Addiction Medicine's inaugural Year in Review report!

I encourage you to take time and review the accomplishments of our faculty, fellows, residents, and students. They reflect the broad impact we are making in the areas of clinical medicine, research, education, policy, and advocacy. You will be amazed at the depth and breadth of their work, across multiple Sections, Departments and Schools at Yale and the dedication our faculty and trainees have in caring for people who use substances and those with addiction.

Addiction Medicine is both an old and new field. Old in the sense that clinicians have long attempted to understand and improve the lives of those with addiction. New in the sense that recent years have brought renewed attention, focus, and momentum in the field because of efforts to address HIV, prescription opioids and pain, fentanyl and overdose, stigma, health equity, and social justice.

Yale has been at the forefront of expanding treatment for substance use and addiction into general medical settings for over 30 years. This includes Adult and Pediatric Primary Care, Emergency Departments, HIV Clinics, Liver Clinics, Cancer Centers, and hospitals. Our faculty and trainees are conducting cutting-edge research, providing timely, high-quality, and easily accessible care, and cultivating an environment of continuous learning and innovation which attracts and develops national and international leaders.

We comprise specialists in addiction medicine *and* internal medicine, infectious disease, liver disease, pulmonary and critical care medicine, emergency medicine, pediatric and adolescent medicine, anesthesiology, hospital medicine, family medicine, and primary care. We also work closely with our colleagues in the Schools of Public Health, Nursing, Management, and Law to address many interdisciplinary issues.

It is with great pride that I encourage you to explore our first Year-in-Review. Please feel free to contact me with any thoughts or feedback you have.



**David A. Fiellin, MD, FASAM**


Professor of Medicine and Emergency Medicine, Yale School of Medicine  
Professor of Health Policy and Management, Yale School of Public Health  
Vice Chief, Faculty Affairs, Section of General Internal Medicine  
Director, Yale Program in Addiction Medicine



“Our motto, ‘No wrong door,’ means that our breadth cuts across traditional medical disciplines and schools so that wherever a person presents to the medical system, someone is prepared to help them achieve their goals of care.”


# Program Updates

The Yale Program in Addiction Medicine (YPAM) operates across four pillars - clinical practice, education, research, and policy.




## **Clinical Practice**

Evidence-based clinical care delivered in outpatient, inpatient, community-based and general medical settings.




## **Education**

Training and education in evidence-based addiction care spanning medicine, nursing, public health, and allied health professions.



## **Research**

Rigorous and innovative scientific inquiry to advance prevention, treatment, and harm reduction strategies, for substance use, addiction, and related conditions.



## **Policy**

Advising and advocacy at the local, state, and national levels to facilitate legislation, regulation, clinical guidelines, and best practices that enhance access to equitable, quality care for the communities we serve.

# Clinical Practice

For people with substance use disorder, every point of care presents an opportunity for connection to treatment and support services. The Yale Program in Addiction Medicine (YPAM) offers a robust spectrum of clinical services in community-based outpatient clinics, affiliated hospitals, and specialty care practices. Advancing the integration of substance use treatment into general medical settings and supporting adaptive models of care, including mobile and street-based medicine, are cornerstones of YPAM's clinical practice mission.


Clinical programs affiliated with YPAM offer a range of services for substance use and substance use disorders, supported by a diverse faculty and multidisciplinary health professions trainees. Core clinical services include

- The inpatient [Yale Addiction Medicine Consult Service \(YAMCS\)](#), which services the York Street and Saint Raphael campuses of Yale New Haven Hospital (YNHH)
- Outpatient clinics at the [APT Foundation](#) as well as the [Addiction Recovery Clinic](#) embedded within Cornell Scott-Hill Health Center
- A nationally renowned [emergency department-initiated buprenorphine program](#)
- A school- and hospital-based [pediatric and adolescent consult service](#)
- Specialty clinics serving populations such as individuals navigating community reentry after incarceration, those with medical co-morbidities (e.g., HIV, Hepatitis C, chronic pain), and those with concomitant psychiatric conditions.

The 2024-25 academic year saw the launch of new innovative care models, such as [InMOTION](#), Connecticut's first clinic on wheels. The year also brought continued growth and expansion for integrated services tailoring treatments to the whole patient, such as those offered by the [Yale Clinic for Alcohol and Addiction Treatment](#) in Hepatology. In collaboration with the American Society of Addiction Medicine (ASAM), YPAM faculty helped launch the [Providers Clinical Support System - Medications for Alcohol Use Disorder](#), offering clinical guidance and trainings to multidisciplinary healthcare professionals. In turn, YPAM continues to advance access to the latest evidence-based treatments for opioid use disorder, with new long-acting injectable formulations of buprenorphine now available in selected primary care and specialty outpatient treatment settings, inpatient treatment settings, as well as the emergency department.

Started in 2018, **YAMCS has helped over 12,000 patients** with substance use disorders admitted to Yale New Haven Hospital. The multidisciplinary team brings cutting-edge addiction treatment to the bedside and navigates complex systems and processes spanning the continuum of care to help patients when they need it most.

**Melissa Weimer, DO, MCR**  
Medical Director, YAMCS  
Associate Professor, of Medicine, Yale School of Medicine, and Epidemiology (Chronic Diseases), Yale School of Public Health



The YAMCS team sees approximately **3,000 patients annually** across YNHH's York Street and Saint Raphael campuses.

# Treating Alcohol Use in the Setting of Liver Disease Through Integrated Care

adapted from an article originally published by Rachel Martin in YSM News

End-stage liver disease occurs as a result of severe chronic liver injury, leading to failure of the liver to perform vital functions and life-threatening complications. It is usually a consequence of cirrhosis resulting from progression of a chronic liver problem such as alcohol-associated liver disease or hepatitis C infection. The only cure for cirrhosis is liver transplantation, however many patients do not qualify or are unable to access it due to organ shortage and other factors. In late 2023, a generous gift enabled Yale to establish a new pilot program to provide behavioral health care for patients with advanced liver disease not receiving transplant-related care.

A common concern among patients in the program with alcohol use disorder (AUD) is receiving AUD care after discharge from the hospital to help them avoid a return to alcohol consumption. Furthermore, coordination of care for treatment of liver disease in tandem with AUD can prove challenging. Patients often have to seek and receive care at multiple locations, spanning different clinical programs and teams.

Established in 2021, the Yale Clinic for Alcohol and Addiction Treatment in Hepatology, seeks to address these concerns before they can turn into barriers to care and adverse health outcomes. Clinic director, Lamia Haque, MD, MPH, assistant professor of medicine (digestive diseases), hails the behavioral health pilot program as “revolutionary.” Her clinic often partners with the program to ensure comprehensive care for her patients with liver disease and AUD. Since launching collaborations like this one, Haque observes that her patients have benefitted from more seamless transitions of care in service of their complex needs, and that medical residents, fellows, and other trainees have gained exposure to an innovative integrated care model in action. Haque, who completed her own fellowship training in addiction medicine, digestive diseases, and advanced transplant hepatology all at Yale



School of Medicine, hopes to expand educational opportunities at Yale at the intersection of addiction medicine and hepatology, including trainee programming and peer-to-peer learning.



**Lamia Haque, MD, MPH**  
Assistant Professor of Medicine  
(Digestive Diseases)

“There aren’t many places in the country where this kind of care is co-located. Our patients need more than just treatment for their end-stage medical complications; they also need care that addresses the factors leading to those complications and aims to improve their quality of life.”

# First Legal Mobile Retail Pharmacy and Clinic Provides Care to People Where They Are

adapted from an article originally published by Viviana Sofía Flores Rivera in YSM News



Yale Medicine (YM) and Yale New Haven Health System (YNHHS) have launched the first mobile retail pharmacy and clinic in the nation to bring health care to people where they live. InMOTION serves Connecticut communities with a goal to make better health accessible to anyone disconnected from the health care system for any reason.

InMOTION's mobile services include:

- Filling prescriptions and giving vaccinations
- Clinical care in-person and via tele-health
- Phlebotomy services
- Primary care and care for chronic diseases such as diabetes and high blood pressure
- Care for infectious diseases such as HIV and Hepatitis C
- Wound care
- Treatment for opioid and alcohol use disorder and naloxone distribution
- Mental health care
- Social service assistance for housing applications and financial navigation

InMOTION is expected to help reduce disparities across the patient population. "Health inequities are a longtime barrier to access that YM and YNHHS are deeply committed to help-

ing remove throughout the communities we serve with innovative initiatives like this," says Margaret McGovern, MD, PhD, CEO of YM and executive vice president and chief physician executive of YNHHS.

"This is the first time in my whole academic and clinical career that I feel like I'm actually doing something that might change how we deliver health care to people," says Sandra Springer, MD, professor of medicine (infectious diseases), who received federal grant funding from the National Institute on Drug Abuse (NIDA) to implement this project and conduct related research. "We are very excited to be part of this innovative project to provide access to underserved communities," says Vinay Sawant, RPh, MPH, MBA, executive director, Pharmacy Services, YNHHS. "The mobile pharmacy services strive to increase access through financial navigation, grant and manufacturer support, and a new partnership with Dispensary of Hope to provide select medications to eligible patients."



**Sandra Ann Springer, MD**  
Professor of Medicine & Associate  
Clinical Professor of Nursing

**"What's the point of the clinical and research work we do if we're not really reaching people and improving their care?"**

# Clinical Tools & Resources

click each icon to learn more

Yale Program in Addiction Medicine (YPAM) faculty, staff, and trainees regularly contribute to clinical resources and guidance in addiction medicine for multidisciplinary audiences. Selected resources from the last year are listed below. These tools are free and publicly accessible.



## **Providers Clinical Support System (PCSS) Medications for Alcohol Use Disorder (MAUD)**

Funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) with leadership from YPAM faculty members, Melissa Weimer, DO, MCR, Stephen Holt, MD, MS, and multi-institutional collaborators, PCSS-MAUD is a continuing education unit-accredited online resource for healthcare professionals offering education and training on alcohol use disorder. YPAM faculty contributors to PCSS-MAUD to date include Cara Borelli, DO; Shawn Cohen, MD; Lamia Haque, MD, MPH; and Erica Heiman, MD.



## **American Society of Addiction Medicine (ASAM) Shared Medical Appointments: Enhancing OUD Treatment Success**

Developed by ASAM with leadership from YPAM faculty members Dana Cavallo, PhD, and Stephen Holt, MD, MS, this resource guides clinical teams in implementing shared medical appointments (SMAs) in their opioid use disorder (OUD) treatment setting. Clinicians may consult this guide to learn more about benefits of SMAs in OUD care, considerations SMA implementation, barriers and facilitators, practice pearls, and key references.



## **The Curbsiders Addiction Medicine Podcast**

Hosted by Yale Addiction Medicine Fellowship alumna (2021), Carolyn Chan, MD, MHS, assistant clinical professor of psychiatry and behavioral neuroscience at the University of Cincinnati College of Medicine, and produced by YPAM faculty members Kenneth Morford, MD, and Shawn Cohen, MD, among others, this podcast offers bite-sized learning in clinical addiction medicine across a range of topics. YPAM faculty guests have included William Becker, MD; Shawn Cohen, MD; Lamia Haque, MD, MPH; Stephen Holt, MD, MS; Lisa Puglisi, MD; Kimberly Sue, MD, PhD; Jeanette Tetrault, MD; and Melissa Weimer, DO, MCR.



## **YPAM's SaferSubstanceUse.org**

Designed for people who use drugs and clinicians providing substance use and addiction care, [safersubstanceuse.org](https://safersubstanceuse.org) provides practical, evidence-based guidance on strategies for safer substance use and infection prevention, medications for addiction treatment, and how to start a conversation about harm reduction. This resource is made possible by the Yale New Haven Hospital Medical Staff Fund and was recently expanded to include information about xylazine.



## **Pain, Opioids, and Worker Wellness Training Curriculum**

Created in by YPAM in partnership with the Yale Occupational & Environmental Medicine Program, Pain, Opioids, and Worker Wellness is a free, live, continuing education unit-accredited virtual curriculum for clinicians. Via self-directed and live, interactive learning activities, participants hone their skills in clinical care for acute and chronic pain, assessment and treatment of opioid use disorder, and facilitation of improved functional status and return to work. This curriculum is made possible by support from The Hartford's Stigma Free Program.

# Education

YPAM is preparing the next generation of addiction-trained healthcare professionals by providing clinical and research training to medical, advanced practice nursing, and physician associate (PA) students, as well as medical residents and clinical fellows.

Core educational offerings of YPAM include:

- The Accreditation Counsel for Graduate Medical Education (ACGME)-accredited [Yale Addiction Medicine Fellowship](#) for physicians
- The Substance use Skills Training to Advance INtegrated care ([SUSTAIN](#)) [fellowship and faculty development program](#) for advanced practice providers (APPs)
- The Collaborative Behavioral Health and Addiction Medicine in Primary Care ([CHAMP](#)) [program](#) for medical residents and physician associate students
- K12 career development opportunities for junior faculty, and
- Bimonthly public [Addiction Medicine Grand Rounds](#) offering continuing medical education (CME) credits


These and other addiction medicine education and training programs at Yale are supported with federal funds from the Health Resources and Services Administration (HRSA), Substance Abuse and Mental Health Services Administration (SAMHSA), and National Institute on Drug Abuse (NIDA), among other sources. Under the leadership of Jeanette Tetrault, MD, professor of medicine and of epidemiology (chronic diseases), the Yale Addiction Medicine Fellowship for physicians trains four fellows annually. Entering its third year, SUSTAIN, directed by Kenneth Morford, MD, assistant professor of internal medicine, includes one of the first addiction medicine fellowship for APPs in the country, training one fellow annually and offering professional development activities for Yale School of Nursing and Physician Associate Program faculty.

Launched last fall, the SAMHSA-funded Responsive Integration of Substance use Education (RISE) program, led by Cara Borelli, DO, instructor in internal medicine, is bridging didactic and experiential offerings in addiction medicine spanning the Yale School of Medicine and School of Nursing under a comprehensive interdisciplinary longitudinal curriculum.

The Yale Program in Addiction Medicine continues to build on a strong foundation of innovative, comprehensive training programs, responding to the needs of learners, patients, and communities. We are beyond proud of the faculty and trainees who contribute to our rich educational environment.

**Jeanette Tetrault, MD**

Associate Director, Education & Training, YPAM  
Professor of Medicine, Yale School of Medicine, and  
Epidemiology (Chronic Diseases), Yale School of  
Public Health



Addiction medicine fellows pose alongside colleagues at the APT Foundation, a low-barrier opioid treatment program and outpatient clinic in New Haven where fellows rotate regularly.

# 2024-25 Fellowship Graduates

**Joshua Bia, MD**

**Residency:** Emergency Medicine, Yale School of Medicine  
**Post-Fellowship Plans:** Instructor, Emergency Medicine, Yale School of Medicine



**Alyssa Chang, DO**

**Residency:** Family Medicine, Community Hospital East  
**Post-Fellowship Plans:** Clinical Associate/Instructor, Internal Medicine, Yale School of Medicine



**Bella Kalayilparampil, MD, MPH**

**Residency:** Internal Medicine, Heersink School of Medicine  
**Post-Fellowship Plans:** Clinical Assistant Professor, Internal Medicine, University of Pennsylvania Perelman School of Medicine



**Molly Perri, MD**

**Residency:** Med/Peds, Pritzker School of Medicine, U Chicago  
**Post-Fellowship Plans:** Assistant Professor of Clinical Family Medicine, University of Illinois College of Medicine



**Stephanie Stamatis, PA-C**

**PA Program:** Yale School of Medicine Physician Associate Program  
**Post-Fellowship Plans:** Hospitalist at Yale New Haven Hospital



On June 10, 2025, fellows gathered with family, friends, faculty and staff for the Yale Program in Addiction Medicine's (YPAM) annual fellowship graduation celebration, hosted by Patrick O'Connor, MD, MPH, the Dan Adams and Amanda Adams Professor of General Internal Medicine. Remarks from YPAM leadership were followed by a presentation of certificates, refreshments, and festivities.

Left to right: (standing) Stephanie Stamatis, PA-C; Alyssa Cheng, DO; Bella Kalayilparampil, MD, MPH; Jenna McDermit, FNP (APP Fellow); (kneeling) Joshua Bia, MD; Molly Perri, MD



# Celebrating Six Years of CHAMP

The Collaborative Behavioral Health and Addiction Medicine in Primary Care (CHAMP) program, federally funded by the Health Resources and Services Administration, celebrated six years this June. Since launching in 2019, CHAMP has provided 14 Yale Primary Care-Internal Medicine residents, 35 physician associate (PA) students, and 20 multidisciplinary faculty members enhanced training in addiction medicine and behavioral health. Five of seven residency training track graduates have gone on to addiction medicine fellowships, and three of four completed their fellowship training at Yale. Program Director, Kenneth Morford, MD, reflects:



CHAMP 2025 residency training track graduates, Rema Elmostafa, MD (left) and Chantel Oldenkamp, MD (right), pose with their graduation certificates alongside CHAMP program faculty leadership.

## Looking back on the last 6 years of CHAMP, what are you most proud of?

“We’ve implemented a program across 3 different training levels (faculty, residents, students) with great success. This model works! We can get someone who has some interest in addiction at the start of training and cultivate that into a career. The 3-year residency training track is particularly innovative. Rotations have been developed for many fields but a track requires sustained commitment over time. I’m proud so many of our residents have gone on to addiction medicine fellowship. They will strengthen and grow the workforce. Many of our PA student graduates have also integrated addiction care into their careers. The interdisciplinary faculty development program has enabled us to enhance addiction training across specialties at Yale.”

## What do you envision for CHAMP 6 years from now?

begin thinking about what CHAMP looks like beyond Yale. I could see expansion to other Connecticut institutions and across the country with some of the foundational elements we’ve developed at Yale to serve new contexts and service landscapes. The residency training track model could be applied to other specialties where addiction training would be valuable (e.g., pediatrics, emergency medicine, and OBGYN). Similarly, training for students can be expanded. We’ve already offered the CHAMP rotation to medical and nursing students. I could see it adapted for students in psychology, pharmacy, social work, dentistry, and other health professions.”

“I’d like to see us expand to other types of learners and

## What wisdom can you share for others seeking to establish similar programs?

“Just start somewhere. Leverage the voices of your trainees. Trainees want this and can help advocate for more addiction education. Hire addiction-trained faculty! Addiction is a leading public health crisis in the United States. Having more health professionals trained in addiction is something that we all need.”



CHAMP faculty, trainees, and loved ones gathered in June to celebrate CHAMP’s 2025 residency training track graduates and the end of the academic year.

# Forging New Paths with SUSTAIN



adapted from an article originally published by Emma Biegacki in YSM News



Fellows Stephanie Stamatis, PA-C, and Jenna McDermit, FNP, prepare with Fellowship Assistant Director, Jared Franzman, PA-C, for morning rounds on the Yale Addiction Medicine Consult Service.

In July 2023, Yale School of Medicine was funded by the Health Resources and Services Administration (HRSA) to establish an addiction medicine fellowship for advanced practice providers (APPs), including physician assistants and advanced practice registered nurses. Substance Use Skills Training to Advance INtegrated care (SUSTAIN), now in its third year of implementation, aims to build upon the missions of the Yale Addiction Medicine Fellowship for physicians and the CHAMP program to strengthen interdisciplinary addiction medicine training initiatives at Yale. By providing specialized training to APP trainees and faculty, Program Director Kenneth Morford, MD, and Assistant Director, Jared Franzman, PA-C, hope to expand the addiction-trained workforce in general medical settings where barriers to treatment are most often encountered, and to integrate addiction expertise wherever patients may seek care. “Clinicians in all fields come across patients with substance use disorders,” Franzman reflects, continuing “the skills our APP fellows are developing will not only allow them to be experts in addiction medicine but will also prepare them to feel comfortable treating substance use in any field they choose to enter. My ultimate goal is for addiction medicine as a standard part of medical education for all APPs. Hopefully, starting the SUSTAIN fellowship is just the beginning of broader mentorship and education in this area.”

Since launching, four APP faculty members have completed SUSTAIN’s year-long faculty development program. Inaugural APP fellow, Stephanie Stamatis, graduated in February 2025, and has since taken a position in hospital medicine at Yale New Haven Hospital, where she will continue to collaborate in the treatment of patients with substance use disorder alongside YPAM faculty and clinical associates.

Through SUSTAIN, I’ve built trusting relationships with patients and engaged in open conversations about substance use. These connections, and collaboration with an interdisciplinary team, have helped me develop strong clinical skills. I hope to expand low-barrier access to treatment and harm reduction programming, and to educate others in delivering respectful care grounded in trust and dignity.

**Jenna McDermit, FNP**  
SUSTAIN APP Fellow



SUSTAIN faculty leadership, clinical affiliates, fellows, and family break bread at a dinner hosted by Dr. Morford in honor of Stephanie Stamatis, P-AC, on the occasion of her fellowship graduation.

# Across the Country: National Engagement Through Grand Rounds

Yale Addiction Medicine Grand Rounds (AMGR) are free, continuing medical education (CME)-accredited lectures offered twice per month on a diverse array of topics related to substance use and addiction. Since transitioning to a fully virtual and public format in 2020, AMGR engagement has grown exponentially with attendees tuning in from across the country and, increasingly, around the world.

Speakers invited for the 2024-25 series represented over 13 disciplines in clinical medicine, public health, and the social sciences. Notable topics included medications for addiction treatment, overdose prevention and harm reduction, clinician advocacy in action, withdrawal management, perinatal substance use, integrated care models, primary prevention, cultural and political contexts of substance use, and more.

In September 2024, Jeffrey Samet, MD, MA, MPH, the John Noble Professor in General Internal Medicine and professor of community health science at Boston University Schools of Medicine and Public Health, delivered the 8th Annual Schottenfeld Lecture, in honor of Richard Schottenfeld, MD. His presentation, “10 Million People, 67 Communities: A Community-Based Cluster RCT to Reduce Opioid Overdose Deaths,” detailed findings of the HEALing Communities Study.

## 2024-25 AMGR BY THE NUMBERS



**21** grand rounds sessions held



**49** states represented by attendees



**40** countries represented by attendees



Left to right: Drs. Richard Schottenfeld, Jeffrey Samet, and David Fiellin, at the 8th Annual Schottenfeld Lecture on September 10, 2024.



Scan to access free, on-demand lectures from the 2024-25 AMGR series and prior years.

# Around the World: New Haven to Jordan

adapted from articles originally published by Rebecca Minahan-Rowley and Devina Buckshee in YSM News

The Yale and University of Jordan (UJ) Joint Training Program in Addiction Medicine, established with support from the Yale Institute for Global Health Global Addictions Network and United States (US) Embassy in Amman, facilitates a learning exchange between Yale and UJ regarding prevention and treatment of substance use disorders and attention to cultural competency. Since the program's launch in 2021, faculty, staff, and students in the Yale Schools of Medicine and Public Health have traveled to Amman, and their counterparts at UJ to New Haven, to engage in collaborative training, share knowledge and skills, and develop new resources. Activities have included student-led discussions on public health and drug policy in the US and in Jordan, clinical skills workshops, didactic presentations for multidisciplinary health professions students, and site visits to community partners. The ultimate mission of this work, shares Srinivas Muvvala, MD, MPH, associate professor of psychiatry and member of Yale faculty leadership for the joint training program, is to facilitate exchange and improve addiction-related teaching in both institutions. Says Muvvala, "there is so much to learn



Leadership of the Yale-UJ training program during a recent visit of the University of Jordan team to New Haven and the Yale University campus.

from various cultures and positive and negative aspects of health care delivery." In September 2024, accomplishments of the joint program in intercultural curriculum development were presented at the International Society for Addiction Medicine conference in Istanbul, Türkiye. In May, the program published in the *American Journal of Pharmaceutical Education* on creation of a novel course in substance use for pharmacy students in Jordan.

Collaboration with UJ is driving new research on substance use and mental health outcomes. As of 2022, associate professor of epidemiology, Kaveh Khoshnood, MPH, PhD, also a member of Yale faculty leadership for the joint program, has been funded through the Global Health Faculty Network's Hecht Award to conduct a mixed-methods study with people living in and recently migrated from the Middle Eastern North African region. Khoshnood and team presented this work at Addiction Medicine Grand Rounds in April 2025, in their talk entitled, "Substance Use and Mental Health Among Forcibly Displaced Populations and Humanitarian Crises."



From left to right: Jeanette Tetrault, MD; Mayyada Wazaify, PharmD; Srinivas Muvvala, MD, MPH; Rebecca Minahan-Rowley, LMSW.

# Research

Yale Program in Addiction Medicine (YPAM) faculty conduct research funded by federal, institutional, and foundation grants including observational studies, randomized controlled trials, implementation science, policy analysis, and ethnographic research designed to discover, evaluate, implement, and disseminate effective strategies for substance use and addiction diagnosis, treatment, prevention, and harm reduction.

Core faculty published **over 130 papers** during the 2024-25 academic year, and several faculty members held positions of leadership on the editorial boards of prominent journals in addiction medicine and review committees for prestigious grants and awards. New research grants received this year from government, foundation, and institutional funders will support investigation across a range of topics, including but not limited to:

- Medication treatments for insomnia in people with opioid use disorder
- Opioid use disorder and overdose prevention among children and adolescents
- Medications for vaping cessation
- Traditional and family-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) in pediatric primary care
- Racial stress and alcohol craving among Black adults with alcohol use disorder

Published in *JAMA Network Open* July 2024, a study led by Gail D'Onofrio, MD, MS, Albert E. Kent Professor of Emergency Medicine at Yale School of Medicine (YSM), and of epidemiology (chronic diseases) at Yale School of Public Health, and multi-institutional colleagues, found high treatment efficacy and low risk for precipitated withdrawal among people with fentanyl use initiated on buprenorphine in the emergency department. Another study led by Benjamin Howell, MD, MPH, MHS, assistant professor of medicine at YSM, and published in *Drug and Alcohol Dependence*, highlights the critical role medications for opioid use disorder play in preventing overdoses. Among many active clinical trials led by YPAM faculty and colleagues, Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS), will enter its final year of data collection in July 2025. The National Institute on Drug Abuse-funded study aims to promote HIV risk reduction among people who inject drugs.



The multidisciplinary CoMPASS research team, comprising YPAM faculty, institutional colleagues, and community partners, held their 2024 annual retreat in December.

It's been an incredible privilege and inspiration to work with the CoMPASS team these last few years, where everyone involved is deeply committed to serving individuals impacted by opioid use disorder and advancing HIV prevention.

**E. Jennifer Edelman, MD, MHS**  
Primary Investigator, CoMPASS  
Professor of Medicine,  
Yale School of Medicine

# Research at a Glance

click each icon to learn more



Core faculty and colleagues published 130+ papers during the 2024-25 academic year in such journals as *JAMA Internal Medicine*, *Journal of General Internal Medicine*, *American Journal of Public Health*, *Pediatrics*, *Annals of Emergency Medicine*, *Annals of Internal Medicine*, *Lancet HIV*, *Boston Medical Journal*, *Drug & Alcohol Dependence*, *Journal of Addiction Medicine*, *International Journal on Drug Policy*, and *Harm Reduction*, among others.

Core faculty lead four research centers alongside multi-institutional collaborators, including the Clinical Trials Network (CTN) Consortium Node, the Veterans Affairs Family of Research Cohorts (VACo), the Integrative Management of Chronic Pain and Opioid Use Disorder for Whole Recovery - Yale Organizations (IMPOWR-YOU), and the Yale Pharmacoepidemiology Working Group.



A growing collection of publicly accessible tool kits developed to disseminate practice-changing research are available on the YPAM website. Currently available toolkits support implementation of emergency-department initiated buprenorphine, substance use disorder treatment integration for primary care and HIV clinics, as well as stepped care and contingency management for alcohol use.

Program core and affiliated faculty, including long-established leaders in the field and early-career investigators, won 10 awards during the 2024-25 academic year recognizing exceptional contributions to research and addiction science, bestowed by federal agencies, professional associations, nonprofit organizations, and other entities.



# Seven-day Buprenorphine is Safe for Those with Minimal Opioid Withdrawal

adapted from an article originally published by Mallory Locklear in YaleNews



Individuals with minimal opioid withdrawal are often not prescribed sublingual buprenorphine, because the treatment itself can induce precipitated withdrawal. A recent Yale study finds that a new seven-day, extended-release (XR) version of the medication is safe and effective for people with opioid use disorder (OUD) experiencing minimal symptoms of withdrawal.

Withdrawal is measured through the Clinical Opioid Withdrawal Scale ranging from 0 to 48. Individuals were invited to participate in the study if they scored 7 or less, indicating minimal to mild withdrawal. Only 7% of participants, and 3% of those at the higher end of the minimal withdrawal scale, experienced precipitated withdrawal with XR buprenorphine. Findings, reported in *JAMA Network Open*, indicate XR-buprenorphine can be used before moderate to severe withdrawal develops, which, researchers say, means more people can receive treatment and more lives can be saved.

“This is a game-changer,” said Gail D’Onofrio, MD, MS, Albert E. Kent Professor of Emergency Medicine at Yale School of Medicine, professor

of epidemiology (chronic diseases) at Yale School of Public Health, and lead author of the study. “The ED is a huge access point for OUD treatment, but around 50% of patients with OUD who come to the ED are not at sufficient levels of withdrawal to use sublingual buprenorphine.” With XR-buprenorphine, she explains, “we can not only initiate treatment in patients with minimal withdrawal immediately during their visit, but can protect them from overdosing for seven days, not just 24 hours. That time can give people a chance to find a long-term treatment provider.” In this study, 73% of participants went on to receive medication treatment at the end of the seven-day dose.


 [Click to read this study.](#)



**Gail D’Onofrio, MD, MS**  
Albert E. Kent Professor of Emergency Medicine  
and Epidemiology (Chronic Diseases)

“The goal now is to get hospitals to approve use of this treatment in their emergency departments, inpatient services, and outpatient clinics. This is a really important new option. It’s an opportunity to save a life.”

# Interdisciplinary Collaboration in Alcohol Research



YCARE faculty leadership pose with YCARE 2024 collaborators, presenters, and attendees at the Anylan Center in October.

YCARE, which held its inaugural conference in 2022, is sponsored by Yale Departments of Internal Medicine and Psychiatry, Yale Program in Addiction Medicine, and Yale Liver Center, with additional support from the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

This year's conference featured a dynamic day of learning, interaction, and collaboration with podium talks, interactive breakout sessions, a panel discussion, poster presentations, and more. Six post-graduate and postdoctoral associates in Yale Department of Psychiatry were recognized with abstract awards for their promising research.

YCARE, led by Banini, is also helmed by co-directors David Fiellin, MD, professor of internal medicine and emergency medicine at YSM, and of health policy and management at Yale School of Public Health, Graeme Mason, PhD, professor of radiology and biomedical imaging and of psychiatry at YSM, and Sherry McKee, PhD, Albert E. Kent Professor of Psychiatry at YSM.

The third annual Yale Conference for Alcohol Research and Education (YCARE) was held on October 19, 2025, in New Haven, Conn., with 90 in attendance.

Bubu Banini, MD, PhD, assistant professor of medicine (digestive diseases) at Yale School of Medicine (YSM) and Director of YCARE, describes the annual conference as "a forum for specialists and non-specialists to meet with the goal of acquiring and disseminating new information in the broad area of alcohol-related research." Two major aims of YCARE are to increase cross-disciplinary collaborations in alcohol research and disseminate information about alcohol and associated diseases, to academic and non-academic communities.



Banini, Fiellin, and faculty colleagues pose with 2024 YCARE abstract award winners following presentation of awards certificates.

# Medications ‘Gold Standard’ in Preventing Overdoses

adapted from an article originally published by Amy Anderson in YSM News



A new Yale-led retrospective cohort study published in *Drug and Alcohol Dependence* examined a range of treatments for opioid use disorder and identified those most successful in preventing overdoses.

Investigators examined data of over 4,000 overdose survivors spanning a 19-month period. The analysis found that people who took methadone or buprenorphine had a lower risk of further overdoses compared to those who did not take the medications. The research team also found no statistical differences between inpatient treatment, such as rehabilitation or detox, and receiving no treatment at all. This suggests inpatient treatment has no independent effect on subsequent overdoses.

The study emphasizes the importance and value of using medications to treat patients with opioid use disorder. “This real-world experience confirms what we see in clinical trials,” says Benjamin Howell, MD, MPH, assistant professor of medicine (general medicine) at Yale School of Medicine (YSM) and lead author of the study. Howell continues, “medications improve a range of outcomes like treatment retention, drug use, criminalized behavior, and even employment.”

Indeed, shares co-author, David Fiellin, MD, professor of medicine (general medicine) and of emergency medicine at YSM and of health policy and management at Yale School of Public Health (YSPH), “these medications are considered the gold standard for the treatment of opioid use disorder by the National Institutes of Health and other authoritative bodies, and they are effective because they prevent withdrawal and decrease craving.” The researchers hope the data will inform public policy and regulations at the local, state, and federal levels.

YSM and YSPH faculty partnered with several agencies for the study, including the Department of Mental Health and Addiction Services, the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research, and the Office of Surveillance and Epidemiology.

 [Click to read this study.](#)



**William Becker, MD**  
Professor of Medicine  
(General Internal Medicine)

“Medications prevent overdoses and ultimately save lives. So it follows that we should continue to pursue efforts to reduce barriers to accessing them.”

# 2024-25 Conference Snapshots



# Policy

The Yale Program in Addiction Medicine (YPAM) conducts policy research and advises institutional, local, state, and federal partners in order to advance access to evidence-based treatments and harm reduction strategies for substance use and substance use disorders, reduce substance use stigma and discrimination, and facilitate community awareness.

Efforts primarily focus on the effect that policies and laws have on:

- Cost and quality of addiction treatment
- Substance use and addiction-related health disparities
- Overdose prevention and response
- Multilevel regulation of prevention, treatment, and harm reduction
- Clinical guidelines
- Health professions workforce development, and
- Special populations such as individuals who are unhoused, involved in the criminal legal system, or living with other chronic medical or psychiatric conditions

In 2023, a team of YPAM faculty and staff led by Benjamin Howell, MD, MPH, assistant professor of medicine, was requested by the Connecticut Department of Mental Health and Addiction Services to prepare a report to the state Opioid Settlement Advisory Committee (OSAC) regarding use of opioid settlement funds. The [2024 Connecticut Opioid REsponse \(CORE\) Report](#) presented current evidence and promising interventions, delineating funding priorities for the OSAC's consideration. These priorities continue to inform funding decisions. Proposals submitted to the OSAC must indicate the CORE priorities they will target. In 2024-25, 12 proposals received funding, bringing the total number of funded proposals to 18 since the OSAC's inception in 2022.

Over the course of the academic year, program core and affiliated faculty published widely on policy and advocacy topics, including but not limited to improving equitable, affordable access to addiction treatment, preserving patients' civil rights in treatment settings, decriminalizing drug paraphernalia, centering black and queer voices in harm reduction, and including people who inject drugs in HIV eradication efforts. Selected publications are highlighted on page 24 of this report.

Addiction takes a societal toll, and YPAM engages across its clinical, educational, and research efforts with issues of public policy interest. We aim to generate evidence and expertise that directly inform policies at the local, state, and federal levels to reduce the personal and societal harms of substance use and addiction.

**Benjamin Howell, MD, MPH**  
Assistant Professor of Medicine, Yale School of Medicine



YPAM Faculty, fellows, and staff OnPoint NYC, one of the first sanctioned overdose prevention centers in the United States.

# Why Do So Few U.S. Psych Hospitals Use Medications for Opioid Use Disorder?

adapted from an article originally written by Rachel Tompa for YSM News




Over six million people in the United States (US) are living with opioid use disorder (OUD), yet the most evidence-based treatments—medications for opioid use disorder (MOUD)—are significantly underused. A new study led by researchers at Yale School of Medicine (YSM) and published in *JAMA Network Open* found that fewer than half of US psychiatric hospitals make MOUD available to their patients. There is a significant overlap between patients with OUD and psychiatric disorders. Research has shown that more than a third of treatment-seeking patients with OUD have a psychiatric disorder as well. Patients at psychiatric hospitals are even more likely to need OUD treatment than the general population.

Studies have shown that the FDA-approved MOUD buprenorphine and methadone reduce risk of death from overdose by 50% or more, are generally safe, and help patients reduce their opioid use. Of 1,021 psychiatric hospitals surveyed, only 490 reported having these treatments available. The survey only asked about medication availability, not how regularly they are offered to patients, so the actual use of these treatments at psychiatric hospitals could be even lower. Researchers postulated that a

combination of stigma and lack of provider education may be at fault for low availability of MOUD in psychiatric hospitals. Methadone and buprenorphine are highly regulated (naltrexone has fewer regulations), but easier to prescribe in hospitals than in outpatient settings, which not all clinicians may realize. Outdated perceptions that addiction must be overcome through willpower alone may prevent clinicians from offering MOUD. “We are missing an opportunity to initiate treatment in the hospital,” explained Srinivas Muvvala, MD, MPH, associate professor of psychiatry, and co-author of this study. “We don’t discuss whether we should start diabetes or hypertension medications. When it comes to addiction, stigma and bias can prevent clinicians from recognizing that this condition can be treated,” Muvvala shared.

 [Click to read this study.](#)



**Shawn Cohen, MD**  
Assistant Professor of Medicine  
(General Internal Medicine)

“These are incredible, lifesaving medications. Our goal is that people should be able to access these evidence-based treatments wherever they interact with the medical system.”

# Advising Connecticut on State Opioid Settlement Spending

## CORE Funding Priorities

- Increase **Access to the Most Effective Medications** (Methadone and Buprenorphine) for Opioid Use Disorder Across Diverse Settings
- Reduce **Overdose Risk and Mortality**, Especially Among Individuals at Highest Risk and with Highest Need with Linkage to Treatment, Naloxone, and Harm Reduction
- Improve the **Collection, Analysis, Sharing, and Use of Data** Across Agencies and Organizations Relevant to Addressing the Opioid Overdose Crisis
- Invest in **Training and Support** to Increase the Size of the Addiction Workforce and Help Non-Specialists Provide Services
- Simultaneously Deploy and Evaluate Select **Primary, Secondary, and Tertiary Prevention** Strategies
- Invest in Efforts to Reduce **Community Stigma** Against Opioid Use Disorder and Opioid Use Disorder Treatments
- Address **Social Determinants and Structural Needs** of At-Risk and Impacted Populations



Scan to visit the CORE website and learn more about this initiative.


[Full 2024 CORE Report](#)

[OSAC Allocations Tracker](#)

[News & Updates](#)

[Data Toolbox](#)

## CORE Team



Benjamin Howell, MD, MHS, MPH

David Fiellin, MD

Emma Biegacki, MPH

Robert Heimer, PhD

Gail D'Onofrio, MD, MS

William Becker, MD

Kimberly Sue, MD, PhD

click each icon to read the article

# 2024-25 Policy Publications Spotlight



## **Discordance Between Insurance Coverage of Antiviral Medications and Nicotine Replacement Therapy Among Individuals With Human Immunodeficiency Virus Who Smoke**

Bernstein SL, Yager JE, Sigel K, Porter E, Do T, Payne E, Bold K, Ledgerwood D, Edelman EJ. *J Addiction Med.* 2024 Jul-Aug 01;18(4):404-407.

Insurance coverage gaps limit ability of people with HIV on antiretroviral therapy to also receive medical management for tobacco use. This may undermine the efficacy of antivirals. Mandated insurance coverage of nonprescription nicotine replacement therapy may improve the health of this population.



## **Drawing on Black and Queer Communities' Harm Reduction Histories to Improve Overdose Prevention Strategies and Policies**

Johnson S, Sue KL. *AMA J Ethics.* 2024 Jul 1;26(7):E580-586.


Histories of Black and queer community-based harm reduction practices can inform harm reduction policy and guide development and implementation of overdose prevention interventions.



## **State Investment in Emergency Department Buprenorphine Pays Off**

D'Onofrio G, Cole JB, Perrone J. *JAMA.* 2025 Feb 19; 333 (14): 1209-1211

The emergency department is a logical setting to provide equitable substance use treatment access and medication initiation, yet it continues to be underused and underfunded.



## **Plans to End HIV Should Address Substance Use**

Springer SA. *Lancet HIV.* 2024 Dec;11(12):e792-e793.

Global efforts to end HIV should include integrated evidenced-based effective substance use prevention and treatment services along with rapid pre-exposure prophylaxis and antiretroviral therapy for people who use drugs.



## **Civil Rights Laws for People With Opioid Use Disorder in the Emergency Department**

South AM, Hawk K, Friedman S, Lofwall MR, Fanucchi LC, Cohen SM. *J Addiction Med.* 2025 Mar 24.

Advocates for a more effective emergency department response to opioid use disorder can use civil rights laws to press for the adoption of evidence-based practices for people with opioid use disorder.

# Awards & Recognition

**Kammarauche Aneni, MBBS, MHS**

Career Development Award, National Institute on Drug Abuse

**Joshua Bia, MD**

Ruth Fox Scholarship, American Society of Addiction Medicine

**Emma Biegacki, MPH**

Internal Medicine Service Excellence Award, Yale Department of Internal Medicine, Yale School of Medicine

**Gail D'Onofrio, MD, MS**

John P. McGovern Award for Excellence in Medical Education, Association for Multidisciplinary Education and Research in Substance use and Addiction

James L. Sorensen Distinguished Treatment and Research Mentor Award, College on Problems of Drug Dependence

Appointed Co-Director of Neuro-Emergency Medicine K12 Scholars Program, National Institute on Drug Abuse

**Gregg Gonsalves, PhD**

Appointed Fellow, Infectious Disease Society of America

**Angela Haeny, PhD**

2025 Research Excellence Award, Yale Office of Health Equity Research

**Ayana Jordon, MD, PhD**

Presidential Early Career Award for Scientists and Engineers, National Institutes of Health

**Amy Justice, MD, PhD**

John M. Eisenberg National Award for Career Achievement in Research, Society of General Internal Medicine

**Jennifer Kapo, MD**

2024 Top Doctors, *Connecticut Magazine*

**Robert Kerns, PhD**

2025 Award for Excellence in Health Psychology Research, Society for Health Psychology

Appointed Fellow, United States Association for the Study of Pain

**Brian Kiluk, PhD**

2024 Spielberger EMPathy Award. American Psychological Foundation

2025 Research Impact Award, Society of Addiction Psychology

**Haidong Lu, PhD**

Appointed Statistical Editor, Journal of Addiction Medicine

**Ted Melnick, MD, MHS**

Mount Sinai Emergency Medicine 30<sup>th</sup> Anniversary Distinguished Alumni Award, Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai

**Jaimie Meyer, MD, MS**

Appointed to the American Society for Clinical Investigation

**Srinivas Muvvula, MD, MPH**

Stephen Fleck Award for Clinician Educator Excellence, Yale School of Medicine

# Awards & Recognition continued

**Patrick O'Connor, MD, MPH**

David C. Lewis Service to AMERSA Award, Association for Multidisciplinary Education and Research in Substance use and Addiction

2024 Top Doctors, *Connecticut Magazine*

**Ijeoma Opara, PhD, MPH, LMSW**

Presidential Early Career Award for Scientists and Engineers, National Institutes of Health

Excellence in Interdisciplinary Studies Impact Award, Growing in Grace

**Molly McInness Perri, MD**

Ruth Fox Scholarship, American Society of Addiction Medicine

**Yusuf Ransome, MPH, DrPH**

Public Voices Fellowship, Yale Women Faculty Forum

**Julia Shi, MD**

Voluntary Faculty Award for Addiction Medicine Education, Department of Internal Medicine, Yale School of Medicine

**Rajita Sinha, PhD and colleagues**

ISBRA Diversity Award, Research Society on Alcohol

**Sandra Ann Springer, MD and colleagues**

2025 Community Award - Staff Appreciation & Recognition Champions Awards, Integrating Substance Use Treatment Research with Infectious Disease for Everyone (InSTRIDE) Program Team, Yale School of Medicine

**Melissa Weimer, DO, MCR**

2nd Century of Women at Yale: Emerging Leaders in Internal Medicine

Public Voices Fellowship, Yale Women Faculty Forum

**Sarah Yip, PhD**

Appointed to Board of Directors, APT Foundation

# Appointments & Promotions

**Sara Edmond, PhD**

Appointed Assistant Professor, Internal Medicine, Yale School of Medicine

**Abigail Friedman, PhD**

Appointed Director of Online and Non-Degree Programs, Yale School of Public Health

**Ariadna Forray, MD**

Appointed Associate Dean and Director of the Office for Women in Medicine and Science, Yale School of Medicine

**Sami Hamdan, MD, MPH**

Appointed Instructor, Internal Medicine. Yale School of Medicine

**Kenneth Morford, MD**

Appointed Medical Director, Yale Physician Associate Program

**Jody Sindelar, PhD**

Appointed Professor Emeritus, Department of Health Policy and Management. Yale School of Public Health

**Sarita Soares, MD**

Promoted to Associate Professor, Internal Medicine

Appointed Co-Director of the Yale Primary Care Internal Medicine Residency Program

# In the Media

click each title to  
read the article

## NATIONAL

An Effective Treatment for Opioid  
Addiction Exists. Why Isn't it Used More?  
*The New York Times*

Abuse of ADHD Medication in Schools: A  
Crucial Wake-up Call  
*CBS News*

Combination OUD Treatment Safe During  
Pregnancy  
*Medpage Today*

Could Ozempic Be Our Next Tool in Fighting  
the Overdose Crisis? Surprising Research  
Suggests So  
*Salon*

Every Hospital Should Offer Addiction  
Treatment  
*Medpage Today*

Evidence of Fentanyl Cut with Tranquilizer  
Xylazine Found Near US-Mexico Border  
*United Press International*

Experts Reveal the Subtle Signs That You're  
on the Road to Alcoholism...As Experts Say  
Even One Drink a Year is Unhealthy  
*DailyMail*

FDA Pushes for Buprenorphine Labeling  
Changes to Facilitate Higher Doses  
*Medscape Psychiatry*

Fentanyl Killed Their Kids, and They're  
Desperate for Change. Can Trump Help?  
*USA Today*

Fentanyl Overdoses Remain High - Is Harm  
Reduction the Solution?  
*Newsweek*

Here's What Addiction Specialists Say  
About 'The White Lotus'  
*Bloomberg*

ISAT+CM Improves Short-term Alcohol  
Abstinence in HIV  
*Physician's Weekly*

Medicaid Limits Access to Lifesaving Doses  
of Addiction Care  
*Roll Call*

Nixing the X Waiver Hasn't Yet Vastly  
Expanded Buprenorphine Access  
*Medpage Today*

'Not Knowing Where to Go': Montana's  
Sparse Landscape for Alcohol Detox  
*Montana Free Press*

Safer Opioid Supply, Methadone Effective  
Treatment Options  
*Medpage Today*

Sober in the City: Rethinking Celebration in  
Chicago  
*The TRIIBE*

The Long, Strange History of Nitrous Oxide,  
a Popular Drug Users Have Been Inhaling for  
Hundreds of Years  
*Smithsonian Magazine*

Unique Pain Research Office Eliminated in  
HHS Purge  
*Stat News*

Some Hospitals Are Changing Their  
Response When Babies Are Born Exposed to  
Drugs  
*CNN*

Varenicline Plus Minimal Behavioral Support  
Aids in E-Cigarette Cessation  
*Healio*

What Alcohol Does to Your Brain and Body,  
According to the Latest Science  
*Business Insider*

# In the Media

click each title to  
read the article

## NATIONAL continued

What is Cannabinoid Hyperemesis Syndrome? Here's What to Know and Why Experts Say It's on the Rise  
*PBS News*

What, Exactly, is Moderate Drinking?  
*The New York Times*

What to Know About Fentanyl  
*The New York Times*

Why Some Doctors Are Pushing to End Routine Drug Testing During Childbirth  
*Mother Jones*

Women Are Drinking More - and Doctors Are Worried  
*Wall Street Journal*

Women with Alcohol Use Disorder Have a Different Disease  
*Psychology Today*

## LOCAL

Bold Action Needed to Further Reduce CT Overdose Deaths  
*Connecticut Mirror*

Clinic-Pharmacy Hits the Road  
*New Haven Independent*

For a 'Land of Steady Habits,' CT Has Seen Changes Over 10 Years  
*Connecticut Mirror*

The Problem with Accessing Opioid Treatment in Parts of CT: Getting There  
*Connecticut Mirror*

Yale Doctor: Weight Loss Drugs Also Help Alcohol Cravings  
*WTNH News 8*

## INSTITUTIONAL

Amid Opioid Overdose Crisis, Yale Program in Addiction Medicine Advises State on Drug Company Settlement Spending  
*Yale School of Medicine*

Brain Activity Related to Craving and Heavy Drinking Differs Across Sexes  
*YaleNews*

Community Forum Focuses on Reducing Youth Substance Use  
*Yale School of Medicine*

Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice  
*Yale School of Medicine*

How Overdose Prevention Centers Can Change the Game in the Fight Against the Opioid Epidemic  
*Yale Daily News*

How Social Media Promotion of Vaping Targets Teens  
*Yale School of Medicine*

Quitting Smoking: It's Harder for Women  
*Yale Medicine*

Research Project Studies High Doses of an Opioid Use Disorder Medication Among Veterans  
*Yale School of Medicine*

# In the Media

click each title to  
read the article

## INSTITUTIONAL continued

Restrictions on Methadone, the Most Regulated Therapeutic Drug in the Country, Reduced  
*Yale Daily News*

Tobacco 21 Policies Could Avert More Than Half a Million Premature Deaths  
*Yale School of Public Health*

Tobacco Purchases Rise Following Restrictions on E-Cigarette Sales  
*Yale School of Public Health*

Unhealthy Alcohol Use Among Men who have Sex with Men Taking PrEP for HIV Prevention  
*Yale School of Medicine - Discoveries & Impact*

YSPH Professor Shares Research, Explores Potential Collaborations During Jamaica Visit  
*Yale School of Public Health*

## LISTEN IN: PODCASTS, INTERVIEWS & MORE

Cara Borelli, DO  
**A Chilling Risk of Recreational Nitrous Oxide**  
*NBC News*

David Fiellin, MD  
**Opioid Awareness: Part 1 - Stigma, Intervention, and Resources**  
*Healio Physicianary Podcast*

David Fiellin, MD  
**“Treatment Refractory” Addiction**  
*ASAM Weekly Podcast*

Robert Heimer, PhD  
**How a QR Code Can Help People with Opioid Use Disorder?**  
*WTNH News 8*

Robert Heimer, PhD, and Kenneth Morford, MD  
**COVID-19 and the American Overdose Crisis**  
*Public Health Musings Podcast*

Stephen Holt, MD, MS  
**Diagnosing Alcohol Use Disorder**  
*Primary Care Pearls Podcast*

Stephen Holt, MD, MS  
**Managing Alcohol Use Disorder**  
*Primary Care Pearls Podcast*

Kimberly Sue, MD, PhD  
**Harm Reduction in the Hospital**  
*AMERSA Harm Reduction: Compassionate Care for People Who Use Drugs Podcast*

Melissa Weimer, DO, MCR  
**Could a Ban on Mini Alcohol Bottles Come to Connecticut?**  
*WTNH News 8*

# Core Faculty



**David Fiellin, MD**  
Professor of Medicine (General Medicine) and Emergency Medicine, Yale School of Medicine; Professor of Health Policy and Management, Yale School of Public Health; Director, Yale Program in Addiction Medicine



**Jeanette Tetrault, MD**  
Professor of Medicine (General Medicine), Yale School of Medicine, and of Epidemiology (Chronic Diseases), Yale School of Public Health; Associate Director of Education and Training, Yale Program in Addiction Medicine



**Stephen Baldassarri, MD, MHS**  
Assistant Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine



**William Becker, MD**  
Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Cara Borelli, DO**  
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Deepa Camenga, MD, MHS**  
Associate Professor of Emergency Medicine, Yale School of Medicine; Associate Director of Pediatric Programs, Yale Program in Addiction Medicine



**Shawn Cohen, MD**  
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Edouard Coupet Jr., MD, MS**  
Assistant Professor of Medicine, Yale School of Medicine



**Gail D'Onofrio, MD, MS**  
Albert E. Kent Professor of Emergency Medicine, Yale School of Medicine; Professor of Epidemiology (Chronic Diseases), Yale School of Public Health



**Joseph Donroe, MD**  
Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine



**E. Jennifer Edelman, MD, MHS**  
Professor of Medicine (General Medicine), Yale School of Medicine



**Caroline Falker, MD**  
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Sami Hamdan, MD, MPH**  
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Lamia H. K. Haque, MD, MPH**  
Assistant Professor of Medicine (Digestive Diseases); Director, Yale Clinic for Alcohol and Addiction Treatment in Hepatology,



**Kathryn Hawk, MD, MHS**  
Associate Professor of Emergency Medicine, Yale School of Medicine; Associate Professor of Epidemiology (Chronic Diseases), Yale School of Public Health



**Rebekah Heckmann, MD, MPH, MPA**  
Assistant Professor of Emergency Medicine and Anesthesiology, Yale School of Medicine



**Erica Heiman, MD**  
Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine




**Thomas Hickey, MD, MS**  
Assistant Professor of Anesthesiology, Yale School of Medicine

# Core Faculty



**Stephen Holt, MD, MS**

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine; Director, Addiction Recovery Clinic



**Haidong Lu, PhD**

Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine; Assistant Professor of Epidemiology (Chronic Diseases), Yale School of Public Health



**Benjamin Howell, MD, MPH, MHS**

Assistant Professor of Medicine (General Internal Medicine) < Yale School of Medicine



**Ryan McNeil, PhD**

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine; Associate Director, Harm Reduction Research, Yale Program in Addiction Medicine



**Jaimie Meyer, MD, MS**

Associate Professor of Medicine (Infectious Diseases), Yale School of Medicine; Associate Professor of Epidemiology (Chronic Diseases), Yale School of Public Health



**Kenneth Morford, MD**

Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Patrick O'Connor, MD, MPH**

Dan Adams and Amanda Adams Professor of General Medicine, Yale School of Medicine



**Lisa Puglisi, MD**

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Sarita Soares, MD**

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Sandra Ann Springer, MD**

Professor of Medicine (Infectious Diseases), Yale School of Medicine; Associate Clinical Professor of Nursing, Yale School of Nursing



**Kimberly Sue, MD, PhD**

Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Minhee Sung, MD**

Assistant Professor of Medicine (General Internal Medicine), Yale School of Medicine



**Melissa Weimer, DO, MCR**

Associate Professor of Medicine (General Internal Medicine), Yale School of Medicine; Associate Professor of Epidemiology (Chronic Diseases), Yale School of Public Health; Medical Director, YAMCS

# Affiliated Faculty

Adam Ackerman, MD, Hospital Medicine  
Kammarauche Aneni, MBBS, MHS, Child Psychiatry  
Lydia Aoun-Barakat, MD, Medicine (Infectious Diseases)  
Declan Barry, PhD, Psychiatry  
Anne C. Black, PhD, Medicine (General Internal Medicine)  
Susan Busch, PhD, Health Policy and Management  
Jenna Butner, MD, Medicine (General Internal Medicine)  
Dana Cavallo, PhD, Psychiatry  
Marek Chawarski, PhD, Psychiatry and Emergency Medicine  
Christopher Cutter, PhD, Psychiatry  
Ellen Lockard Edens, MD, MPE, Psychiatry  
Sara Edmond, PhD, Medicine (General Internal Medicine)  
John Encandela, PhD, Psychiatry  
Ariadna Forray, MD, Psychiatry  
Abigail Friedman, PhD, Health Policy and Management  
Lisa Fucito, PhD, Psychiatry  
Abbe Gluck, JD, Law  
Gregg Gonsalves, PhD, Epidemiology (Microbial Diseases)  
Lauretta Grau, PhD, Epidemiology (Microbial Diseases)  
Robert Heimer, PhD, Epidemiology (Microbial Diseases) and Pharmacology  
Gretchen Hermes, MD, PhD, Psychiatry  
Ayana Jordan, MD, PhD, Psychiatry  
Amy Justice, MD, PhD, Medicine (General Internal Medicine)  
Jennifer Kapo, MD, Palliative Medicine  
Robert Kerns, PhD, Psychiatry  
Kaveh Khoshnood, PhD, MPH, Epidemiology (Microbial Diseases)  
Brian Kiluk, PhD, Psychiatry  
John McDonagh, MD, Medicine (General Internal Medicine)  
Sherry McKee, PhD, Psychiatry  
Ted Melnick, MD, MHS, Emergency Medicine and Biostatistics  
Brent Moore, PhD, Psychiatry  
Srinivas Muvvala, MD, MPH, Psychiatry  
Stephanie O'Malley, PhD, Psychiatry  
Ijeoma Opara, PhD, LMSW, MPH, Social and Behavioral Sciences  
Manuel Paris, PsyD, Psychiatry  
Ismene Petrakis, MD, Psychiatry  
Marc Potenza, PhD, MD, Psychiatry and Neuroscience  
Yusuf Ransome, MPH, DrPH, Social and Behavioral Sciences  
Elizabeth Roessler, MMSc, PA-C, Medicine (General Internal Medicine)  
Julia Shi, MD, Medicine (General Internal Medicine)  
Rajita Sinha, PhD, Psychiatry and Neuroscience  
Daniel Tobin, MD, Medicine (General Internal Medicine)  
David Vlahov, DNP, Nursing and Epidemiology (Microbial Diseases)  
Emily Wang, MD, Medicine (General Internal Medicine) and Social and Behavioral Sciences  
Henry Yaggi, MD, MPH, Medicine (Pulmonary, Critical Care, and Sleep Medicine)

# Program Staff

## **Operational**

Emma Biegacki, MPH, Program Manager  
Toni Boulay, Project Coordinator  
Carolyn Dellaquila, Senior Administrative Assistant  
Rebecca Minahan-Rowley, LMSW, Project Manager

## **Clinical Research**

Jessica McKenzie, MA, Research Associate III  
Svetlana Vassillieva, MD, MS, Associate Director, Clinical Research  
Raiza Rossi, PhD, Post-Doctoral Associate  
June-Marie Weiss, MA, MEd, Senior Project Manager

## **Yale Addiction Medicine Consult Service**

Tracy Bachinski, LPN  
Amy Bopp, APRN  
Jared Franzman, MMSc, PA-C  
Beth Klink, LCSW  
Shayne McCarty  
John O'Neil, LCSW  
Lauryn Tetreault, MMSc, PA-C  
Marion Whittle

# Support Our Work

YPAM is enhanced by the generous support of our donors. A gift of any amount can meaningfully advance our mission and goals, and make an impact on the work we do to improve care and outcomes for people impacted by substance use and addiction.

## Ways to Give

### Direct Donation

Donations in any amount are accepted online via Yale University's institutional giving portal. Donors will be asked to complete a short form indicating the gift amount, type, contact information, and payment method. Donations via check should be made payable to Yale's Department of Internal Medicine, Yale University, with Yale Program in Addiction Medicine indicated in the check memo, and sent to the following address:

### Mailed Check

Checks should be made payable to the Yale Department of Internal Medicine, Yale University, with Yale Program in Addiction Medicine indicated in the check memo.

#### Via US MAIL

Yale School of Medicine  
Attn: Aliza Elwell  
P.O. Box 7611  
New Haven, CT 06519-0611

#### Via FED-EX or UPS

Office of Development  
Yale School of Medicine  
Attn: Aliza Elwell  
157 Church Street  
New Haven, CT 06510

### Philanthropic Partnership

Independent philanthropists and foundations interested in partnering with YPAM to provide operational support or targeted funding to one or more areas of interest are invited to contact Director of Development, Clinical and Healthcare Delivery, Aliza Elwell, directly at [aliza.elwell@yale.edu](mailto:aliza.elwell@yale.edu) or 203-524-4974.

### Other Options

Other ways to give to our program include gifts of marketable securities, planned giving and bequests, and corporate matching. Contact the Office of Development to learn more about how YPAM can help meet your charitable giving interests and goals.



Scan to visit Yale University's institutional giving portal for the Yale Program in Addiction Medicine.

## Yale School of Medicine Office of Development



157 Church Street,  
New Haven, CT 06510



203-432-2206



[development.gifts@yale.edu](mailto:development.gifts@yale.edu)



[medicine.yale.edu/about/giving/](https://medicine.yale.edu/about/giving/)

Thank you for your interest and investment in our work.



YALE PROGRAM IN  
**ADDICTION  
MEDICINE**